Treatment of symptoms of violations of bronchial secretion and sputum excretion, especially in acute bronchopulmonary diseases, such as acute bronchitis; in exacerbations of chronic diseases of the respiratory system.
FLUDITEK 2% COMPOSITION OF THE MEDICINAL PRODUCT
active substance: carbocisteine
Fluditec 2% 1 ml of syrup contains 20 mg of carbocisteine
excipients: glycerin, methylparaben (E 218), sucrose, orange-yellow dye S (E 110), banana flavor, sodium hydroxide, purified water
Fluditec 5% 1 ml of syrup contains 50 mg of carbocisteine
auxiliary substances: glycerin, methylparaben (E 218), sucrose, orange-yellow dye S (E 110), patented blue V (E 131) dye, caramel flavor, sodium hydroxide, purified water.
FLUDITEK 2% DOSAGE FORM
Fluditec 2% is a clear orange liquid with a banana taste and smell.
Fluditec 5% is a clear liquid of pale green color with a brown tint with a caramel smell.
FLUDITEK 2% PHARMACOLOGICAL GROUP
Drugs used for coughs and colds. Mucolytic agents. Carbocisteine. ATC code R05С B03.
Carbocisteine affects the gel phase of the mucus of the respiratory tract: by breaking the disulfide bridges of glycoproteins, it causes the liquefaction of the excessively viscous secretion of the bronchi, promotes the excretion of sputum.
The mucoregulatory effect of carbocisteine is associated with the activation of sialic transferase, an enzyme of the goblet cells of the bronchial mucosa. Carbocisteine normalizes the quantitative ratio of acidic and neutral sialomucins of bronchial secretion, restores its viscosity and elasticity. It activates the activity of the ciliated epithelium and improves mucociliary clearance. Promotes regeneration of the mucous membrane of the respiratory tract, normalizes its structure, reduces hyperplasia of goblet cells and, as a result, reduces mucus production. Restores the secretion of immunologically active IgA (specific protection) and the amount of sulfhydryl groups of mucus components (non-specific protection). It has an anti-inflammatory effect due to the kinininibuyuchoi activity of sialomucins, which leads to a decrease in edema and bronchial obstruction.
Treatment of symptoms of disorders of bronchial secretion and sputum excretion, especially in acute bronchopulmonary diseases, for example, in acute bronchitis with exacerbations of chronic diseases of the respiratory system.
A history of allergic reaction to any of the components of the drug (especially methylparaben or other salts of parahydroxybenzoates)
peptic ulcer of the stomach and duodenum during an exacerbation
I trimester of pregnancy, due to insufficient data on teratogenic and embryotoxic effects.
PROPER USE SAFETY
A productive cough is a fundamental defense mechanism of the bronchopulmonary system and as such should not be suppressed. An irrational combination of drugs that modify bronchial secretion with cough suppressants and / or substances that reduce secretion (atropine group).
The use of mucolytic agents can lead to impaired bronchial patency in newborns. In children of the first year of life, the ability to clear the airways from bronchial secretions is limited due to age-related anatomical and physiological features. Any mucolytic agents should not be used in infants.
Treatment should be reviewed if there is no effect or increased symptoms of the disease.
The drug contains sucrose, therefore, patients with hereditary lack of glucose tolerance, glucose-galactose malabsorption or sucrose-isomaltose insufficiency should avoid taking the drug.
Careful medical supervision is necessary for the discharge of purulent sputum, high temperature.